

# Efstathios Kastritis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1528920/publications.pdf>

Version: 2024-02-01

652  
papers

28,122  
citations

11608

70  
h-index

7333

152  
g-index

658  
all docs

658  
docs citations

658  
times ranked

26049  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.   | 5.1  | 3,343     |
| 2  | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.  | 13.5 | 2,432     |
| 3  | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.  | 5.1  | 1,866     |
| 4  | Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 834-847.   | 2.0  | 1,354     |
| 5  | Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. <i>Journal of Clinical Oncology</i> , 2005, 23, 8580-8587.  | 0.8  | 990       |
| 6  | New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549. | 0.8  | 735       |
| 7  | A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. <i>Blood</i> , 2013, 121, 3420-3427.   | 0.6  | 385       |
| 8  | Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.  | 1.9  | 351       |
| 9  | Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. <i>Annals of Oncology</i> , 2009, 20, 117-120.                                 | 0.6  | 347       |
| 10 | Diagnosis of monoclonal gammopathy of renal significance. <i>Kidney International</i> , 2015, 87, 698-711.   | 2.6  | 339       |
| 11 | The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.                            | 4.1  | 330       |
| 12 | International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.   | 0.8  | 294       |
| 13 | Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.   | 13.9 | 291       |
| 14 | European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.   | 1.7  | 289       |
| 15 | Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1031-1037.   | 0.8  | 273       |
| 16 | Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.   | 13.9 | 268       |
| 17 | Pathogenesis and treatment of renal failure in multiple myeloma. <i>Leukemia</i> , 2008, 22, 1485-1493.  | 3.3  | 259       |
| 18 | How I treat monoclonal gammopathy of renal significance (MGRS). <i>Blood</i> , 2013, 122, 3583-3590.   | 0.6  | 259       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.   | 3.3 | 259       |
| 20 | Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.  | 1.9 | 232       |
| 21 | Response assessment in Waldenström macroglobulinaemia: update from the 13th International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176.   | 1.2 | 226       |
| 22 | Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. <i>Haematologica</i> , 2006, 91, 968-71.  | 1.7 | 223       |
| 23 | Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 241-250.  | 5.1 | 212       |
| 24 | Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.   | 0.8 | 207       |
| 25 | Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013, 122, 3276-3282.   | 0.6 | 180       |
| 26 | Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. <i>Haematologica</i> , 2007, 92, 1351-1358.   | 1.7 | 179       |
| 27 | Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). <i>Leukemia</i> , 2009, 23, 1152-1157.   | 3.3 | 176       |
| 28 | Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.  | 2.6 | 167       |
| 29 | Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.   | 0.6 | 161       |
| 30 | Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. <i>Haematologica</i> , 2007, 92, 546-549.  | 1.7 | 160       |
| 31 | VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093. | 0.8 | 154       |
| 32 | Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy. <i>International Journal of Cancer</i> , 2012, 131, 1466-1471.  | 2.3 | 150       |
| 33 | Daratumumab plus CyBORd for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.  | 0.6 | 146       |
| 34 | Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. <i>Leukemia</i> , 2013, 27, 947-953.  | 3.3 | 141       |
| 35 | Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5904-5909.   | 0.8 | 139       |
| 36 | Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.  | 0.6 | 138       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. <i>Leukemia</i> , 2013, 27, 423-429.  | 3.3 | 137       |
| 38 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.  | 3.3 | 137       |
| 39 | Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015, 125, 3085-3099.   | 0.6 | 136       |
| 40 | Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.  | 0.6 | 130       |
| 41 | Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.  | 1.7 | 127       |
| 42 | Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. <i>Annals of Oncology</i> , 2014, 25, 195-200.   | 0.6 | 126       |
| 43 | International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.  | 2.8 | 126       |
| 44 | Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. <i>Leukemia</i> , 2010, 24, 1769-1778.  | 3.3 | 120       |
| 45 | Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.  | 2.2 | 119       |
| 46 | The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. <i>Leukemia</i> , 2008, 22, 2247-2256. | 3.3 | 117       |
| 47 | The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. <i>Leukemia</i> , 2014, 28, 2402-2403.   | 3.3 | 115       |
| 48 | Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.  | 1.7 | 112       |
| 49 | Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.  | 0.6 | 108       |
| 50 | Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. <i>Trends in Molecular Medicine</i> , 2022, 28, 542-554.  | 3.5 | 104       |
| 51 | The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.  | 2.8 | 103       |
| 52 | Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.   | 0.8 | 102       |
| 53 | Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.   | 1.4 | 101       |
| 54 | Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. <i>Annals of Oncology</i> , 2012, 23, 2681-2686.      | 0.6 | 98        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.  | 2.2 | 96        |
| 56 | Proteasome inhibitor associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2016, 91, E348-52.   | 2.0 | 95        |
| 57 | Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 904-916.  | 1.2 | 91        |
| 58 | Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.  | 2.5 | 89        |
| 59 | A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012, 119, 5384-5390.   | 0.6 | 88        |
| 60 | Recent advances in the management of AL Amyloidosis. <i>British Journal of Haematology</i> , 2016, 172, 170-186.   | 1.2 | 88        |
| 61 | Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 2150-2154.   | 0.8 | 87        |
| 62 | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor- $\kappa$ B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. <i>Acta Oncologica</i> , 2007, 46, 221-229.  | 0.8 | 83        |
| 63 | Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.   | 2.0 | 83        |
| 64 | Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. <i>Blood</i> , 2019, 133, 710-723.   | 0.6 | 82        |
| 65 | Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012, 87, 861-864. | 2.0 | 81        |
| 66 | Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. <i>Radiology</i> , 2017, 282, 484-493.  | 3.6 | 81        |
| 67 | European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.  | 3.3 | 81        |
| 68 | The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2006, 106, 297-303.   | 2.0 | 78        |
| 69 | Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2021, 798, 149014.  | 3.9 | 76        |
| 70 | Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2008, 49, 890-895.   | 0.6 | 74        |
| 71 | Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.                                   | 2.0 | 73        |
| 72 | Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.   | 1.7 | 72        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Treatment of light chain deposition disease with bortezomib and dexamethasone. <i>Haematologica</i> , 2009, 94, 300-302.  | 1.7 | 70        |
| 74 | Cardio-oncology: A Focus on Cardiotoxicity. <i>European Cardiology Review</i> , 2018, 13, 64.   | 0.7 | 65        |
| 75 | How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2019, 134, 2022-2035.   | 0.6 | 65        |
| 76 | Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.   | 0.8 | 65        |
| 77 | The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. <i>Annals of Oncology</i> , 2005, 16, 307-313.  | 0.6 | 64        |
| 78 | Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.  | 0.4 | 64        |
| 79 | Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv41-iv50.  | 0.6 | 63        |
| 80 | Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. <i>Leukemia</i> , 2010, 24, 1206-1212.  | 3.3 | 62        |
| 81 | BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.   | 0.6 | 62        |
| 82 | Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.  | 0.8 | 62        |
| 83 | Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.           | 1.2 | 61        |
| 84 | Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. <i>Haematologica</i> , 2009, 94, 372-379.  | 1.7 | 60        |
| 85 | Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. <i>Cancer</i> , 2005, 103, 2629-2635.  | 2.0 | 58        |
| 86 | Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.  | 1.2 | 58        |
| 87 | Somatic mutations of adenomatous polyposis coli gene and nuclear $\beta$ -catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication. <i>International Journal of Cancer</i> , 2009, 124, 103-108. | 2.3 | 57        |
| 88 | Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.  | 0.6 | 57        |
| 89 | Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.  | 3.3 | 57        |
| 90 | Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.  | 0.4 | 56        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, E60-5.                             | 2.0 | 55        |
| 92  | Increased expression of macrophage inflammatory protein-1 $\alpha$ on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. <i>Leukemia</i> , 2009, 23, 2177-2181. | 3.3 | 54        |
| 93  | Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. <i>American Journal of Hematology</i> , 2014, 89, 803-808.                   | 2.0 | 54        |
| 94  | The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.  | 0.6 | 54        |
| 95  | Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 830-844.   | 2.5 | 54        |
| 96  | A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.   | 3.3 | 53        |
| 97  | Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. <i>BMC Medicine</i> , 2021, 19, 208.   | 2.3 | 52        |
| 98  | Treatment of Relapsed/Refractory Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 143-157.   | 1.8 | 49        |
| 99  | Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.  | 2.0 | 48        |
| 100 | A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.  | 1.7 | 48        |
| 101 | JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. <i>European Journal of Cancer</i> , 2020, 126, 125-135.  | 1.3 | 48        |
| 102 | The evolving role of lenalidomide in the treatment of hematologic malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 497-509.  | 0.9 | 46        |
| 103 | Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment. <i>Oncology</i> , 2007, 73, 290-297.                                     | 0.9 | 46        |
| 104 | Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020, 2020, 1-11.  | 0.6 | 46        |
| 105 | COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.  | 2.2 | 46        |
| 106 | Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem cell transplantation: Results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010, 85, 863-867.                 | 2.0 | 44        |
| 107 | Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.   | 1.7 | 44        |
| 108 | Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.  | 0.6 | 44        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.  | 1.7 | 44        |
| 110 | The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. <i>Gynecologic Oncology</i> , 2005, 99, 376-382.  | 0.6 | 43        |
| 111 | No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.  | 2.0 | 43        |
| 112 | Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.  | 0.8 | 43        |
| 113 | Treatment of plasma cell dyscrasias with lenalidomide. <i>Leukemia</i> , 2008, 22, 1343-1353.  | 3.3 | 42        |
| 114 | The International Prognostic Scoring System for Waldenström's macroglobulinemia is applicable in patients treated with rituximab-based regimens. <i>Haematologica</i> , 2008, 93, 1420-1422.   | 1.7 | 42        |
| 115 | Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.  | 3.4 | 42        |
| 116 | Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 1-7. | 1.4 | 42        |
| 117 | Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8787-8803.   | 2.9 | 41        |
| 118 | Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e299-e309.   | 2.2 | 41        |
| 119 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013, 88, 765-770.   | 2.0 | 40        |
| 120 | Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.   | 3.3 | 40        |
| 121 | Increased Serum Lactate Dehydrogenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 409-413.  | 0.2 | 39        |
| 122 | Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.  | 2.8 | 39        |
| 123 | Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.  | 2.5 | 39        |
| 124 | Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.   | 1.8 | 38        |
| 125 | Serum concentrations of angiogenic cytokines in Waldenström macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. <i>British Journal of Haematology</i> , 2007, 137, 560-568.  | 1.2 | 37        |
| 126 | Novel approaches for reducing free light chains in patients with myeloma kidney. <i>Nature Reviews Nephrology</i> , 2012, 8, 234-243.  | 4.1 | 37        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. <i>European Journal of Haematology</i> , 2013, 91, n/a-n/a. | 1.1 | 37        |
| 128 | Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. <i>Blood</i> , 2016, 128, 405-409.   | 0.6 | 37        |
| 129 | Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.  | 1.1 | 37        |
| 130 | Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.   | 2.5 | 37        |
| 131 | A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.   | 0.6 | 37        |
| 132 | Clinicopathological features of ovarian carcinosarcomas: a single institution experience. <i>Gynecologic Oncology</i> , 2005, 96, 136-142.   | 0.6 | 35        |
| 133 | Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.   | 2.8 | 35        |
| 134 | Immunogenic Cell Death, DAMPs and Prothymosin $\hat{\pm}$ as a Putative Anticancer Immune Response Biomarker. <i>Cells</i> , 2022, 11, 1415.   | 1.8 | 34        |
| 135 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 34-40.                     | 2.0 | 33        |
| 136 | Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. <i>Blood Cancer Journal</i> , 2017, 7, e571-e571.  | 2.8 | 33        |
| 137 | Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <i>Rheumatology International</i> , 2020, 40, 1353-1360.   | 1.5 | 33        |
| 138 | Circulating angiopoietin $\hat{\epsilon}$ 1 to angiopoietin $\hat{\epsilon}$ 2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. <i>International Journal of Cancer</i> , 2012, 130, 735-742.                     | 2.3 | 32        |
| 139 | VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. <i>Leukemia</i> , 2014, 28, 928-934.   | 3.3 | 32        |
| 140 | A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 103-110.   | 0.4 | 31        |
| 141 | Targeted therapies in multiple myeloma. <i>Targeted Oncology</i> , 2009, 4, 23-36.   | 1.7 | 31        |
| 142 | Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014, 92, 308-312.  | 1.1 | 31        |
| 143 | Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. <i>Blood Cancer Journal</i> , 2017, 7, e570-e570.  | 2.8 | 31        |
| 144 | Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.   | 1.1 | 31        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.   | 0.8 | 31        |
| 146 | Sclerostin: a possible target for the management of cancer-induced bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 761-769.   | 1.5 | 30        |
| 147 | Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. <i>Haematologica</i> , 2012, 97, 1699-1703.             | 1.7 | 30        |
| 148 | Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. <i>OncoTargets and Therapy</i> , 2013, 6, 531.   | 1.0 | 30        |
| 149 | Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.   | 1.9 | 30        |
| 150 | Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.  | 2.8 | 29        |
| 151 | A randomized phase 3 study of ixazomib+dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2022, 36, 225-235.  | 3.3 | 29        |
| 152 | Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 50-52. | 1.4 | 28        |
| 153 | Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>European Journal of Haematology</i> , 2010, 85, 1-5. | 1.1 | 28        |
| 154 | Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. <i>Leukemia and Lymphoma</i> , 2011, 52, 2299-2303.                              | 0.6 | 28        |
| 155 | The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. <i>Annals of Oncology</i> , 2012, 23, 722-729.   | 0.6 | 28        |
| 156 | Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012, 89, 10-15.   | 1.1 | 28        |
| 157 | Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2165-2177.  | 0.9 | 28        |
| 158 | The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.  | 1.9 | 28        |
| 159 | Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.   | 1.0 | 28        |
| 160 | Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. <i>HemaSphere</i> , 2020, 4, e454.  | 1.2 | 28        |
| 161 | Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. <i>Haematologica</i> , 2009, 94, 725-728.           | 1.7 | 28        |
| 162 | Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. <i>Blood</i> , 2010, 116, 1574-1574.                             | 0.6 | 28        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.   | 0.6 | 28        |
| 164 | A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. <i>Annals of Oncology</i> , 2004, 15, 1250-1255.   | 0.6 | 27        |
| 165 | Response to bortezomib of a patient with scleromyxedema refractory to other therapies. <i>Leukemia Research</i> , 2011, 35, e209-e211.  | 0.4 | 27        |
| 166 | Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1477-1495.   | 0.9 | 27        |
| 167 | Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.  | 0.6 | 27        |
| 168 | Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment. <i>Urology</i> , 2005, 65, 126-130.  | 0.5 | 26        |
| 169 | Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 994-999.                     | 1.2 | 26        |
| 170 | High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. <i>Leukemia Research</i> , 2010, 34, 399-402.  | 0.4 | 26        |
| 171 | Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 159, 340-351.  | 1.2 | 26        |
| 172 | Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.  | 1.5 | 26        |
| 173 | Emerging antibodies for the treatment of multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 225-237.   | 1.0 | 25        |
| 174 | Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. <i>Scientific Reports</i> , 2019, 9, 3245.  | 1.6 | 25        |
| 175 | High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.  | 2.1 | 25        |
| 176 | A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2010, 116, 988-988.   | 0.6 | 25        |
| 177 | Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.   | 1.1 | 25        |
| 178 | Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.   | 0.6 | 24        |
| 179 | Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241. | 1.4 | 24        |
| 180 | Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.   | 1.7 | 24        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2006, 133, 301-304.  | 1.2 | 23        |
| 182 | An overview of the role of carfilzomib in the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1883-1897.   | 0.9 | 23        |
| 183 | Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> , 2018, 8, 102. | 2.8 | 23        |
| 184 | Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.  | 0.2 | 23        |
| 185 | Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract. <i>Journal of Clinical Oncology</i> , 2008, 26, 1555-1557.  | 0.8 | 22        |
| 186 | Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.  | 2.0 | 22        |
| 187 | Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.  | 1.4 | 22        |
| 188 | Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.  | 0.8 | 22        |
| 189 | Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.   | 1.4 | 22        |
| 190 | A review of the venous thrombotic issues associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 695-706.  | 1.0 | 21        |
| 191 | Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.  | 2.0 | 21        |
| 192 | Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 109.   | 2.8 | 21        |
| 193 | Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.   | 1.4 | 21        |
| 194 | The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. <i>Anticancer Research</i> , 2006, 26, 3865-9.   | 0.5 | 21        |
| 195 | The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2007, 104, 372-376.   | 0.6 | 20        |
| 196 | Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.   | 0.2 | 20        |
| 197 | Bortezomib for AL amyloidosis: moving forward. <i>Blood</i> , 2011, 118, 827-828.  | 0.6 | 20        |
| 198 | Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients. <i>International Journal of Dentistry</i> , 2014, 2014, 1-7.   | 0.5 | 20        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.   | 0.2 | 20        |
| 200 | Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.  | 1.2 | 20        |
| 201 | Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. <i>Medicine (United States)</i> , 2020, 99, e23845.  | 0.4 | 20        |
| 202 | Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study. <i>Blood</i> , 2018, 132, 149-149.  | 0.6 | 20        |
| 203 | Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. <i>Cancer Management and Research</i> , 2013, 5, 37.  | 0.9 | 19        |
| 204 | Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1723-1726.   | 0.6 | 19        |
| 205 | Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. <i>Blood Cancer Journal</i> , 2016, 6, e428-e428.  | 2.8 | 19        |
| 206 | Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. <i>Blood</i> , 2020, 136, 24-26.   | 0.6 | 19        |
| 207 | Validation of the Criteria of Response to Treatment In AL Amyloidosis.. <i>Blood</i> , 2010, 116, 1364-1364.   | 0.6 | 19        |
| 208 | Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience. <i>Oncology</i> , 2006, 70, 265-272.   | 0.9 | 18        |
| 209 | Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11. | 1.4 | 18        |
| 210 | Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.   | 1.2 | 18        |
| 211 | IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 1935-1935.  | 0.6 | 18        |
| 212 | Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.   | 3.6 | 18        |
| 213 | Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 73-76.  | 1.4 | 17        |
| 214 | Thalidomide in the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 681-699.   | 0.7 | 17        |
| 215 | Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience. <i>Tumori</i> , 2011, 97, 25-29.   | 0.6 | 17        |
| 216 | Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.  | 0.6 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. <i>Scientific Reports</i> , 2017, 7, 17802.  | 1.6 | 17        |
| 218 | Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.   | 2.5 | 17        |
| 219 | Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.  | 1.2 | 17        |
| 220 | Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.   | 0.8 | 17        |
| 221 | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.   | 1.2 | 17        |
| 222 | Carboplatin Hypersensitivity Reactions: A Single Institution Experience. <i>Journal of Chemotherapy</i> , 2005, 17, 104-110.   | 0.7 | 16        |
| 223 | Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. <i>Leukemia and Lymphoma</i> , 2007, 48, 754-758.   | 0.6 | 16        |
| 224 | Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. <i>Oncology</i> , 2007, 72, 388-396.   | 0.9 | 16        |
| 225 | Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 56-61.  | 0.2 | 16        |
| 226 | Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.  | 2.0 | 16        |
| 227 | Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 335-340.  | 0.2 | 16        |
| 228 | High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e482-e482.   | 2.8 | 16        |
| 229 | Neutrophil Gelatinase-Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.   | 0.2 | 16        |
| 230 | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25. | 2.8 | 16        |
| 231 | Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2021, 26, 861-879.   | 1.7 | 16        |
| 232 | How I treat relapsed multiple myeloma. <i>Blood</i> , 2022, 139, 2904-2917.  | 0.6 | 16        |
| 233 | Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2006, 102, 124-127.  | 0.6 | 15        |
| 234 | Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. <i>Blood Cancer Journal</i> , 2015, 5, e319-e319.   | 2.8 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2006.   | 1.7 | 15        |
| 236 | Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.   | 2.8 | 15        |
| 237 | Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.   | 1.2 | 15        |
| 238 | Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.  | 3.3 | 15        |
| 239 | Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. <i>Journal of Clinical Oncology</i> , 2021, 39, 8003-8003. | 0.8 | 15        |
| 240 | SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.  | 0.9 | 15        |
| 241 | The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate. <i>Blood</i> , 2005, 106, 637-637.  | 0.6 | 15        |
| 242 | Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. <i>Leukemia and Lymphoma</i> , 2004, 45, 2275-2279.   | 0.6 | 14        |
| 243 | Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 773-779.  | 0.6 | 14        |
| 244 | Managing renal complications in multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 839-850.   | 1.0 | 14        |
| 245 | Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.   | 1.2 | 14        |
| 246 | Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.                                       | 1.6 | 14        |
| 247 | Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. <i>Cells</i> , 2022, 11, 1241.   | 1.8 | 14        |
| 248 | Schnitzler's Syndrome: Increased Levels of Bone Formation and Angiogenesis Factors Are Reduced After Successful Pefloxacin Treatment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 359-362.   | 1.4 | 13        |
| 249 | Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics. <i>Annals of Oncology</i> , 2016, 27, 233-240.   | 0.6 | 13        |
| 250 | Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017, 10, 217-228.  | 1.0 | 13        |
| 251 | Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.   | 0.7 | 13        |
| 252 | The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 93.   | 2.8 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First-Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. <i>Blood</i> , 2020, 136, 26-26. | 0.6 | 13        |
| 254 | The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.. <i>Blood</i> , 2005, 106, 363-363.                             | 0.6 | 13        |
| 255 | High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 425-425.                                       | 0.6 | 13        |
| 256 | Macrophage Inflammatory Protein-1 alpha (MIP-1 $\alpha$ ) Is Increased in Patients with Waldenstrom's Macroglobulinemia and Correlates with the Severity of Disease.. <i>Blood</i> , 2005, 106, 2498-2498.   | 0.6 | 13        |
| 257 | A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.   | 1.8 | 13        |
| 258 | Angiogenesis in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 46-49.  | 1.4 | 12        |
| 259 | Rituximab-Based Treatments in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 59-61.  | 1.4 | 12        |
| 260 | Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 197-205.   | 1.9 | 12        |
| 261 | Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020, 12, 2864.   | 1.7 | 12        |
| 262 | Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5185.  | 1.8 | 12        |
| 263 | Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.  | 2.0 | 12        |
| 264 | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.  | 2.1 | 12        |
| 265 | A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.  | 1.7 | 12        |
| 266 | First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.                           | 0.6 | 12        |
| 267 | Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,. <i>Blood</i> , 2011, 118, 3922-3922.  | 0.6 | 12        |
| 268 | Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. <i>Blood</i> , 2012, 120, 438-438.  | 0.6 | 12        |
| 269 | Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. <i>Blood</i> , 2015, 126, 4178-4178.  | 0.6 | 12        |
| 270 | Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. <i>Anticancer Research</i> , 2007, 27, 611-7.   | 0.5 | 12        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. <i>British Journal of Haematology</i> , 2010, 150, 587-591.   | 1.2 | 11        |
| 272 | Prevention and Treatment of Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 249-257.  | 1.2 | 11        |
| 273 | Proteasome Inhibitors in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 829-840.   | 0.9 | 11        |
| 274 | Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.   | 0.6 | 11        |
| 275 | Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.   | 2.0 | 11        |
| 276 | Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.   | 1.2 | 11        |
| 277 | Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.   | 1.4 | 11        |
| 278 | Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50. | 0.6 | 11        |
| 279 | Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ).. <i>Blood</i> , 2007, 110, 3519-3519.   | 0.6 | 11        |
| 280 | A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.   | 0.6 | 11        |
| 281 | Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7501-7501.   | 0.8 | 11        |
| 282 | A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021, 106, 2940-2946.  | 1.7 | 11        |
| 283 | miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2022, 126, 79-90.   | 2.9 | 11        |
| 284 | Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 115-117.  | 0.2 | 10        |
| 285 | Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.   | 0.6 | 10        |
| 286 | How We Manage Patients with Plasmacytomas. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 227-235.  | 1.2 | 10        |
| 287 | Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.   | 2.3 | 10        |
| 288 | Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.  | 0.2 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | Solid Organ Transplantation in Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 352-364.  | 0.7 | 10        |
| 290 | Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.   | 0.2 | 10        |
| 291 | Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.   | 1.0 | 10        |
| 292 | Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. <i>Oncotarget</i> , 2018, 9, 17797-17809.   | 0.8 | 10        |
| 293 | Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.  | 2.1 | 10        |
| 294 | Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, 746203.   | 2.2 | 10        |
| 295 | Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.  | 2.5 | 10        |
| 296 | Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.   | 2.0 | 10        |
| 297 | An update on the use of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1865-1877.  | 0.9 | 9         |
| 298 | Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.  | 0.6 | 9         |
| 299 | Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.  | 0.8 | 9         |
| 300 | Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.   | 0.6 | 9         |
| 301 | Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.                  | 0.8 | 9         |
| 302 | Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471. | 2.0 | 9         |
| 303 | Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e905-e909.   | 0.2 | 9         |
| 304 | Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021, 13, 1257.   | 1.7 | 9         |
| 305 | How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018, 10, 4248-4268.  | 1.4 | 9         |
| 306 | Hematological malignancies: myeloma. <i>Annals of Oncology</i> , 2006, 17, x136-x143.  | 0.6 | 8         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 325 | Cardiac amyloidosis: in search of the ideal diagnostic tool. <i>Herz</i> , 2021, 46, 9-14.   | 0.4 | 7         |
| 326 | Exercise-Induced Changes in Tumor Growth via Tumor Immunity. <i>Sports</i> , 2021, 9, 46.  | 0.7 | 7         |
| 327 | Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.  | 1.2 | 7         |
| 328 | The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.. <i>Blood</i> , 2009, 114, 1729-1729.  | 0.6 | 7         |
| 329 | Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. <i>Blood</i> , 2010, 116, 2963-2963.  | 0.6 | 7         |
| 330 | Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. <i>Blood</i> , 2012, 120, 1819-1819.   | 0.6 | 7         |
| 331 | Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8546-8546. | 0.8 | 7         |
| 332 | Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. <i>Oncotarget</i> , 2018, 9, 36906-36913.  | 0.8 | 7         |
| 333 | Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. <i>Clinical Nephrology</i> , 2016, 85 (2016), 44-54.  | 0.4 | 7         |
| 334 | Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.  | 2.0 | 7         |
| 335 | Biomarkers in AL Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10916.  | 1.8 | 7         |
| 336 | Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 656-669.   | 1.0 | 7         |
| 337 | Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.   | 0.6 | 7         |
| 338 | Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.   | 1.4 | 7         |
| 339 | The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. <i>Insights Into Imaging</i> , 2022, 13, 55.  | 1.6 | 7         |
| 340 | Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 690-691.   | 4.3 | 6         |
| 341 | Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 235-237.  | 0.2 | 6         |
| 342 | The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. <i>European Journal of Haematology</i> , 2017, 99, 449-458.  | 1.1 | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 343 | Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017, 35, 734-740.   | 0.8 | 6         |
| 344 | Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.  | 0.6 | 6         |
| 345 | Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. <i>Blood</i> , 2008, 112, 869-869.   | 0.6 | 6         |
| 346 | The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.. <i>Blood</i> , 2009, 114, 1815-1815.                          | 0.6 | 6         |
| 347 | How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.  | 0.8 | 6         |
| 348 | Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.   | 1.7 | 6         |
| 349 | Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. <i>Blood</i> , 2021, 138, 153-153.  | 0.6 | 6         |
| 350 | Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. <i>Blood</i> , 2021, 138, 2730-2730.                                     | 0.6 | 6         |
| 351 | Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2005, 26, 627-31.  | 0.3 | 6         |
| 352 | Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study<br>âœœREBUILDâœœ. <i>Cancers</i> , 2022, 14, 2768.  | 1.7 | 6         |
| 353 | Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8076-TPS8076.   | 0.8 | 6         |
| 354 | The role of novel drugs in multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, vii121-vii127.   | 0.6 | 5         |
| 355 | Emerging drugs for WaldenstrÃ¶m's macroglobulinemia. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 45-57.   | 1.0 | 5         |
| 356 | When a little aspirin may be enough. <i>Blood</i> , 2012, 119, 905-906.   | 0.6 | 5         |
| 357 | Current therapy guidelines for Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 194-205.   | 0.7 | 5         |
| 358 | Disease control should be the goal of therapy for WM patients. <i>Blood Advances</i> , 2017, 1, 2483-2485.  | 2.5 | 5         |
| 359 | Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrÃ¶m Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437. | 0.2 | 5         |
| 360 | The Spectrum of Ocular Manifestations in Patients with WaldenstrÃ¶m's Macroglobulinemia. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-10.  | 1.0 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 361 | Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. <i>Blood</i> , 2020, 136, 37-40.   | 0.6 | 5         |
| 362 | Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 44-45.  | 0.6 | 5         |
| 363 | Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 6-7.  | 0.6 | 5         |
| 364 | Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.. <i>Blood</i> , 2007, 110, 1484-1484.   | 0.6 | 5         |
| 365 | Bortezomib+Melphalan+Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.. <i>Blood</i> , 2008, 112, 1727-1727.   | 0.6 | 5         |
| 366 | European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.  | 0.6 | 5         |
| 367 | Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient. <i>Blood</i> , 2013, 122, 3195-3195. | 0.6 | 5         |
| 368 | Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8011-8011.        | 0.8 | 5         |
| 369 | Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5084-5084.  | 0.6 | 5         |
| 370 | Liver and Gastrointestinal Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, e1-e13.  | 0.9 | 5         |
| 371 | Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110583.   | 1.1 | 5         |
| 372 | Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. <i>American Journal of Hematology</i> , 2022, 97, E27.  | 2.0 | 5         |
| 373 | Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3886-3886.                                | 0.6 | 5         |
| 374 | Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021, 138, 2721-2721.  | 0.6 | 5         |
| 375 | Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. <i>Blood</i> , 2021, 138, 159-159.  | 0.6 | 5         |
| 376 | How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. <i>Leukemia and Lymphoma</i> , 2007, 48, 2295-2297.   | 0.6 | 4         |
| 377 | Appraising myc involvement in high risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 551-552.   | 0.6 | 4         |
| 378 | Efficacy and safety of elotuzumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-9.   | 1.0 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 379 | Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq1 1 0.784314 rgBT /Overlo<br>2018, 59, 983-987.  | 0.6 | 4         |
| 380 | Nonlethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 8010-8018.  | 1.6 | 4         |
| 381 | Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.. Blood, 2009, 114, 958-958.   | 0.6 | 4         |
| 382 | Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma. Blood, 2010, 116, 2967-2967.  | 0.6 | 4         |
| 383 | Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. Blood, 2010, 116, 2969-2969.   | 0.6 | 4         |
| 384 | Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. Blood, 2011, 118, 5083-5083.  | 0.6 | 4         |
| 385 | Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment. Blood, 2013, 122, 3090-3090.   | 0.6 | 4         |
| 386 | Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. Blood, 2014, 124, 306-306.  | 0.6 | 4         |
| 387 | Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.  | 0.6 | 4         |
| 388 | A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2736-2736. | 0.6 | 4         |
| 389 | The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. Blood, 2020, 136, 21-21.  | 0.6 | 4         |
| 390 | High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.  | 2.5 | 4         |
| 391 | Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine, 2022, 11, 3355.  | 1.0 | 4         |
| 392 | Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1776-1780.  | 0.6 | 3         |
| 393 | Daratumumab combinations: what can we learn?. Blood, 2017, 130, 957-958.  | 0.6 | 3         |
| 394 | Denosumab for myeloma bone disease: ready for prime time?. Lancet Oncology, The, 2018, 19, 277-278.   | 5.1 | 3         |
| 395 | Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 52-53.   | 1.4 | 3         |
| 396 | Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. Leukemia and Lymphoma, 2020, 61, 3247-3250.  | 0.6 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 397 | Emerging drugs for the treatment of Waldenström macroglobulinemia. Expert Opinion on Emerging Drugs, 2020, 25, 433-444.  | 1.0 | 3         |
| 398 | Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers, 2021, 13, 763.  | 1.7 | 3         |
| 399 | Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. Blood, 2018, 132, 1966-1966.   | 0.6 | 3         |
| 400 | Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.. Blood, 2007, 110, 3609-3609.   | 0.6 | 3         |
| 401 | Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. Blood, 2008, 112, 1725-1725.   | 0.6 | 3         |
| 402 | A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.. Blood, 2009, 114, 428-428.   | 0.6 | 3         |
| 403 | The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD) Tj ETQq1 1 0.784314 rgBT /Over Prospective Multicenter Study. Blood, 2010, 116, 3052-3052.   | 0.6 | 3         |
| 404 | Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.. Blood, 2012, 120, 2919-2919.  | 0.6 | 3         |
| 405 | Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. Blood, 2014, 124, 2113-2113. | 0.6 | 3         |
| 406 | Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood, 2014, 124, 4738-4738.  | 0.6 | 3         |
| 407 | Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenström's Macroglobulinemia. Blood, 2015, 126, 2096-2096.   | 0.6 | 3         |
| 408 | Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. Blood, 2015, 126, 4201-4201.   | 0.6 | 3         |
| 409 | Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.   | 0.6 | 3         |
| 410 | Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. Blood, 2010, 116, 1941-1941.   | 0.6 | 3         |
| 411 | Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. Blood, 2020, 136, 11-11.                                 | 0.6 | 3         |
| 412 | Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. American Journal of Hematology, 2022, 97, 719-730.                                     | 2.0 | 3         |
| 413 | High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further?. Leukemia and Lymphoma, 2008, 49, 4-5.   | 0.6 | 2         |
| 414 | VWF, WM, and angiogenesis: is there a link?. Blood, 2012, 120, 3163-3164.  | 0.6 | 2         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 415 | Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 312-323.   | 0.6 | 2         |
| 416 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.   |     | 2         |
| 417 | Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 989-999.  | 0.5 | 2         |
| 418 | Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1537-1542.   | 1.3 | 2         |
| 419 | Managing myeloma with limited resources in the era of novel drugs. <i>Leukemia and Lymphoma</i> , 2018, 59, 2269-2270.   | 0.6 | 2         |
| 420 | Incidence of Skeletal-Related Events at Diagnosis and at the Time of First Relapse in 463 Patients with Multiple Myeloma Who Received First Line Treatment in a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S333.  | 0.2 | 2         |
| 421 | &lt;p&gt;Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a caseâ€“control study&lt;/p&gt;. <i>Oncotargets and Therapy</i> , 2019, Volume 12, 4195-4202.   | 1.0 | 2         |
| 422 | Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28. | 0.2 | 2         |
| 423 | Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021, 62, 761-763.  | 0.6 | 2         |
| 424 | The Utility of Non-LGE Cardiac Magnetic Resonance Imaging Parameters in the Diagnosis of Cardiac Amyloidosis. <i>Heart Lung and Circulation</i> , 2021, 30, e137-e138.   | 0.2 | 2         |
| 425 | Utilization and tolerance of beta-blockers among patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 31-37.   | 1.4 | 2         |
| 426 | Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. <i>Blood</i> , 2007, 110, 2739-2739.   | 0.6 | 2         |
| 427 | The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. <i>Blood</i> , 2007, 110, 3596-3596.                                     | 0.6 | 2         |
| 428 | Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.. <i>Blood</i> , 2009, 114, 3863-3863.               | 0.6 | 2         |
| 429 | Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.. <i>Blood</i> , 2009, 114, 954-954.  | 0.6 | 2         |
| 430 | Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma. <i>Blood</i> , 2012, 120, 4028-4028.   | 0.6 | 2         |
| 431 | Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenströmâ€™s Macroglobulinemia. <i>Blood</i> , 2013, 122, 1860-1860.  | 0.6 | 2         |
| 432 | The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors. <i>Blood</i> , 2013, 122, 1930-1930. | 0.6 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 433 | Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 4491-4491.  | 0.6 | 2         |
| 434 | Competing Risk Survival Analysis In Patients With Symptomatic Waldenström's Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years. <i>Blood</i> , 2013, 122, 3197-3197.  | 0.6 | 2         |
| 435 | OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S22.  | 0.2 | 2         |
| 436 | Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy. <i>Blood</i> , 2021, 138, 2708-2708.  | 0.6 | 2         |
| 437 | Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality. <i>Blood</i> , 2021, 138, 1636-1636.  | 0.6 | 2         |
| 438 | Future Developments in the Treatment of AL Amyloidosis. <i>Hemato</i> , 2022, 3, 131-152.   | 0.2 | 2         |
| 439 | Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2007, 28, 109-16.  | 0.3 | 2         |
| 440 | Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.   | 1.0 | 2         |
| 441 | Systemic Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1912-1915.   | 2.2 | 1         |
| 442 | Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.  | 0.2 | 1         |
| 443 | Reply to S. Girnius et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2750-2751.   | 0.8 | 1         |
| 444 | Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2016, 2, 1261.  | 3.4 | 1         |
| 445 | Prognosis and risk assessment in AL amyloidosis - There and back again. <i>British Journal of Haematology</i> , 2017, 177, 343-345.   | 1.2 | 1         |
| 446 | Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e40-e41.   | 0.2 | 1         |
| 447 | Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S285-S286.  | 0.2 | 1         |
| 448 | Thalidomide for myeloma: still here?. <i>Lancet Haematology</i> , 2018, 5, e439-e440.   | 2.2 | 1         |
| 449 | A 50-Year-Long Study of Waldenström Macroglobulinemia. <i>Mayo Clinic Proceedings</i> , 2019, 94, 394-396.  | 1.4 | 1         |
| 450 | Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e320-e321. | 0.2 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 451 | Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e5-e6.  | 0.2 | 1         |
| 452 | Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.                   | 1.0 | 1         |
| 453 | Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.   | 0.5 | 1         |
| 454 | Cardiac amyloidosis presenting with coronary artery embolization. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 883.  | 0.5 | 1         |
| 455 | Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018, 132, 3295-3295.      | 0.6 | 1         |
| 456 | Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents.. <i>Blood</i> , 2006, 108, 3586-3586.   | 0.6 | 1         |
| 457 | Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. <i>Blood</i> , 2007, 110, 191-191.   | 0.6 | 1         |
| 458 | Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).. <i>Blood</i> , 2008, 112, 1734-1734.   | 0.6 | 1         |
| 459 | Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.. <i>Blood</i> , 2009, 114, 955-955.  | 0.6 | 1         |
| 460 | Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens. <i>Blood</i> , 2010, 116, 3033-3033.   | 0.6 | 1         |
| 461 | Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. <i>Blood</i> , 2011, 118, 806-806. | 0.6 | 1         |
| 462 | High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease. <i>Blood</i> , 2012, 120, 3967-3967.                        | 0.6 | 1         |
| 463 | Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse. <i>Blood</i> , 2013, 122, 1916-1916.                                    | 0.6 | 1         |
| 464 | Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP. <i>Blood</i> , 2013, 122, 3112-3112.   | 0.6 | 1         |
| 465 | The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). <i>Blood</i> , 2013, 122, 3196-3196.  | 0.6 | 1         |
| 466 | Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.  | 0.6 | 1         |
| 467 | Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. <i>Blood</i> , 2016, 128, 2957-2957.  | 0.6 | 1         |
| 468 | Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. <i>Blood</i> , 2016, 128, 3310-3310.   | 0.6 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 469 | Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 648-648.   | 0.6 | 1         |
| 470 | Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens. <i>Blood</i> , 2007, 110, 4745-4745.  | 0.6 | 1         |
| 471 | The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients. <i>Blood</i> , 2011, 118, 3961-3961.  | 0.6 | 1         |
| 472 | High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2011, 118, 2893-2893.   | 0.6 | 1         |
| 473 | Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients >65 Years of Age Compared to Patients <65 Years. <i>Blood</i> , 2012, 120, 4030-4030.                                   | 0.6 | 1         |
| 474 | The Role of Angiopoietins System in Waldenström's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival. <i>Blood</i> , 2012, 120, 3901-3901.   | 0.6 | 1         |
| 475 | Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies. <i>Blood</i> , 2012, 120, 1786-1786.  | 0.6 | 1         |
| 476 | High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens. <i>Blood</i> , 2012, 120, 935-935. | 0.6 | 1         |
| 477 | Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction. <i>Blood</i> , 2013, 122, 3176-3176.   | 0.6 | 1         |
| 478 | Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013, 122, 1867-1867.                            | 0.6 | 1         |
| 479 | Lenalidomide Administration In Patients With POEMS Syndrome. <i>Blood</i> , 2013, 122, 3235-3235.  | 0.6 | 1         |
| 480 | Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3461-3461.  | 0.6 | 1         |
| 481 | Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Blood</i> , 2015, 126, 4188-4188.   | 0.6 | 1         |
| 482 | Successful treatment with lenalidomide dexamethasone for second relapse of a patient with non-secretory multiple myeloma with extramedullary liver plasmacytomas: A case report. <i>Hematology &amp; Medical Oncology</i> , 2017, 2, .   | 0.1 | 1         |
| 483 | Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. <i>Oncotarget</i> , 2018, 9, 12536-12537.   | 0.8 | 1         |
| 484 | Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenström's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. <i>Blood</i> , 2018, 132, 1978-1978.  | 0.6 | 1         |
| 485 | Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 150-150.  | 0.6 | 1         |
| 486 | Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. <i>Blood</i> , 2018, 132, 1968-1968.          | 0.6 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 487 | Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. <i>Blood</i> , 2021, 138, 1668-1668.   | 0.6 | 1         |
| 488 | High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 2526-2526.   | 0.6 | 1         |
| 489 | Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study. <i>Blood</i> , 2021, 138, 2737-2737.                                    | 0.6 | 1         |
| 490 | Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. <i>Blood</i> , 2021, 138, 2729-2729. | 0.6 | 1         |
| 491 | Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase $\alpha$ . <i>Blood</i> , 2020, 136, 34-35.  | 0.6 | 1         |
| 492 | Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 25-25.   | 0.6 | 1         |
| 493 | Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.   | 0.6 | 1         |
| 494 | T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020, 136, 28-28.          | 0.6 | 1         |
| 495 | Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. <i>Leukemia Research Reports</i> , 2022, 17, 100324.  | 0.2 | 1         |
| 496 | Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study. <i>International Journal of Cardiology</i> , 2022, 363, 102-110.  | 0.8 | 1         |
| 497 | DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA. , 0, , 150-163.   |     | 0         |
| 498 | Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S30-S32.  | 1.4 | 0         |
| 499 | High dose melphalan in primary systemic amyloidosis: status quo?. <i>Leukemia and Lymphoma</i> , 2010, 51, 2149-2151.  | 0.6 | 0         |
| 500 | Waldenström's Macroglobulinemia. , 2013, , 681-699.  |     | 0         |
| 501 | Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S75.                                  | 0.2 | 0         |
| 502 | Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S76-S77.   | 0.2 | 0         |
| 503 | A Revised Staging System for Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S332-S333.  | 0.2 | 0         |
| 504 | Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S332.  | 0.2 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 505 | Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients With AL amyloidosis Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e65-e66.  | 0.2 | 0         |
| 506 | Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e143-e144.   | 0.2 | 0         |
| 507 | RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e143.   | 0.2 | 0         |
| 508 | Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e40.  | 0.2 | 0         |
| 509 | Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e62-e63.  | 0.2 | 0         |
| 510 | Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e115-e116.  | 0.2 | 0         |
| 511 | Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. , 2017, , 239-261.   |     | 0         |
| 512 | Immunomodulatory Agents and Proteasome Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 335-343.   |     | 0         |
| 513 | Primary Systemic Amyloidosis. <i>Hematologic Malignancies</i> , 2018, , 221-245.   | 0.2 | 0         |
| 514 | The role of ibrutinib in Waldenström macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 85-89.  | 0.5 | 0         |
| 515 | Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström's Macroglobulinemia (iNNOVATE). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S283.  | 0.2 | 0         |
| 516 | Clinical Characteristics and Outcomes of Oligosecretory and Non-Secretory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S237-S238.  | 0.2 | 0         |
| 517 | Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, xiii-xiv.   | 0.9 | 0         |
| 518 | Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S235-S236. | 0.2 | 0         |
| 519 | Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S250-S251.  | 0.2 | 0         |
| 520 | Monoclonal Antibodies for Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 841-852.  | 0.9 | 0         |
| 521 | Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S325.  | 0.2 | 0         |
| 522 | Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S331-S332.   | 0.2 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 523 | Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e38-e39.  | 0.2 | 0         |
| 524 | Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e185-e186.   | 0.2 | 0         |
| 525 | Clonal Heterogeneity and Immune Tumor Microenvironment in Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e318-e319.  | 0.2 | 0         |
| 526 | Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e58-e59.  | 0.2 | 0         |
| 527 | Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e190-e191. | 0.2 | 0         |
| 528 | High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e28-e29.   | 0.2 | 0         |
| 529 | Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e121-e122.   | 0.2 | 0         |
| 530 | Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 607571.   | 1.3 | 0         |
| 531 | MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S297-S298.  | 0.2 | 0         |
| 532 | Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.  | 0.6 | 0         |
| 533 | Mutation-dependent treatment approaches for patients with complex multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 189-201.   | 0.4 | 0         |
| 534 | Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14558-e14558.   | 0.8 | 0         |
| 535 | Managing complications secondary to Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2021, 14, 1-12.   | 1.0 | 0         |
| 536 | Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenström's Macroglobulinemia: Correlations with Clinical Data.. <i>Blood</i> , 2005, 106, 2504-2504.  | 0.6 | 0         |
| 537 | Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.. <i>Blood</i> , 2006, 108, 5000-5000.   | 0.6 | 0         |
| 538 | Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006, 108, 3095-3095.                     | 0.6 | 0         |
| 539 | Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5018-5018.  | 0.6 | 0         |
| 540 | Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenström's Macroglobulinemia (WM): Correlations with Clinical Data.. <i>Blood</i> , 2006, 108, 5006-5006.   | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 541 | Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.. Blood, 2007, 110, 4812-4812.  | 0.6 | 0         |
| 542 | The International Prognostic Scoring System for Waldenström's Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. Blood, 2007, 110, 3615-3615.   | 0.6 | 0         |
| 543 | High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.. Blood, 2007, 110, 4781-4781.  | 0.6 | 0         |
| 544 | Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.. Blood, 2007, 110, 4729-4729.  | 0.6 | 0         |
| 545 | The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.. Blood, 2007, 110, 1478-1478.  | 0.6 | 0         |
| 546 | Symptomatic Waldenström's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.   | 0.6 | 0         |
| 547 | Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients. Blood, 2008, 112, 5143-5143.   | 0.6 | 0         |
| 548 | Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis. Blood, 2008, 112, 2731-2731.  | 0.6 | 0         |
| 549 | Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenström's Macroglobulinemia: Implications into the Biology of the Disease. Blood, 2008, 112, 5108-5108.   | 0.6 | 0         |
| 550 | Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). Blood, 2008, 112, 655-655.   | 0.6 | 0         |
| 551 | Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trepine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2008, 112, 5119-5119.   | 0.6 | 0         |
| 552 | The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis.. Blood, 2008, 112, 1728-1728.   | 0.6 | 0         |
| 553 | Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. Blood, 2008, 112, 1726-1726.                         | 0.6 | 0         |
| 554 | Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.. Blood, 2009, 114, 1824-1824. | 0.6 | 0         |
| 555 | Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3334-3334.   | 0.6 | 0         |
| 556 | Validation of the International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).. Blood, 2009, 114, 2845-2845.   | 0.6 | 0         |
| 557 | The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.. Blood, 2009, 114, 2279-2279.  | 0.6 | 0         |
| 558 | Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.. Blood, 2009, 114, 3871-3871.   | 0.6 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 559 | Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.. Blood, 2009, 114, 829-829.   | 0.6 | 0         |
| 560 | Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.. Blood, 2009, 114, 1741-1741.  | 0.6 | 0         |
| 561 | The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.. Blood, 2009, 114, 730-730.  | 0.6 | 0         |
| 562 | Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti-MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo. , 2009, , .  |     | 0         |
| 563 | Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis. Blood, 2010, 116, 3048-3048.  | 0.6 | 0         |
| 564 | Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.. Blood, 2010, 116, 1581-1581.  | 0.6 | 0         |
| 565 | Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years. Blood, 2010, 116, 1947-1947.  | 0.6 | 0         |
| 566 | Increased Expression of Cyclin-D1 on Trepine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents. Blood, 2010, 116, 2965-2965.  | 0.6 | 0         |
| 567 | Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma. Blood, 2010, 116, 2976-2976.   | 0.6 | 0         |
| 568 | Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy. Blood, 2010, 116, 3035-3035.  | 0.6 | 0         |
| 569 | Waldenström's Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects. , 2012, , 277-283.  |     | 0         |
| 570 | Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group. Blood, 2011, 118, 5085-5085.  | 0.6 | 0         |
| 571 | Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?. Blood, 2011, 118, 5091-5091. | 0.6 | 0         |
| 572 | Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival. Blood, 2011, 118, 2894-2894.   | 0.6 | 0         |
| 573 | Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,. Blood, 2011, 118, 3926-3926.  | 0.6 | 0         |
| 574 | Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.  | 0.6 | 0         |
| 575 | Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology. Blood, 2011, 118, 5059-5059.   | 0.6 | 0         |
| 576 | Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,. Blood, 2011, 118, 3920-3920.   | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 577 | Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis. <i>Blood</i> , 2011, 118, 4457-4457.  | 0.6 | 0         |
| 578 | Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations. <i>Blood</i> , 2011, 118, 2872-2872.   | 0.6 | 0         |
| 579 | Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome. <i>Blood</i> , 2011, 118, 1802-1802.   | 0.6 | 0         |
| 580 | Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy. <i>Blood</i> , 2011, 118, 5067-5067.   | 0.6 | 0         |
| 581 | Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 5081-5081.   | 0.6 | 0         |
| 582 | High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens. <i>Blood</i> , 2011, 118, 5082-5082.  | 0.6 | 0         |
| 583 | Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients. <i>Blood</i> , 2011, 118, 1811-1811.  | 0.6 | 0         |
| 584 | Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System. <i>Blood</i> , 2011, 118, 4396-4396.  | 0.6 | 0         |
| 585 | Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 3918-3918.  | 0.6 | 0         |
| 586 | Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. <i>Blood</i> , 2012, 120, 948-948.  | 0.6 | 0         |
| 587 | The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation. <i>Blood</i> , 2012, 120, 1849-1849.                         | 0.6 | 0         |
| 588 | Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. <i>Blood</i> , 2013, 122, 1866-1866.   | 0.6 | 0         |
| 589 | Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 1861-1861.  | 0.6 | 0         |
| 590 | Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens. <i>Blood</i> , 2013, 122, 3091-3091. | 0.6 | 0         |
| 591 | Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. <i>Blood</i> , 2013, 122, 3130-3130.  | 0.6 | 0         |
| 592 | Multiple Myeloma Patients ≥40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3226-3226.   | 0.6 | 0         |
| 593 | Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers. <i>Blood</i> , 2013, 122, 3194-3194.  | 0.6 | 0         |
| 594 | Circulating Levels of Angiogenic Cytokines in Waldenström's Macroglobulinemia: Clinical Correlations. <i>Current Angiogenesis</i> , 2014, 2, 104-109.   | 0.1 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 595 | Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.  | 0.6 | 0         |
| 596 | Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.  | 0.6 | 0         |
| 597 | High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.   | 0.6 | 0         |
| 598 | No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. Blood, 2014, 124, 4752-4752.   | 0.6 | 0         |
| 599 | Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.   | 0.6 | 0         |
| 600 | The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462. | 0.6 | 0         |
| 601 | Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.   | 0.6 | 0         |
| 602 | Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.  | 0.6 | 0         |
| 603 | Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications. Blood, 2014, 124, 276-276.  | 0.6 | 0         |
| 604 | Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.   | 0.6 | 0         |
| 605 | Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.  | 0.6 | 0         |
| 606 | Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.                                  | 0.6 | 0         |
| 607 | Circulating Adams-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.             | 0.6 | 0         |
| 608 | Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.  | 0.6 | 0         |
| 609 | Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia. , 2015, , .   |     | 0         |
| 610 | The patient with myeloma. , 2015, , 1276-1291.  |     | 0         |
| 611 | Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. Blood, 2015, 126, 1832-1832.                    | 0.6 | 0         |
| 612 | Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. Blood, 2015, 126, 3250-3250.              | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 613 | The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.   | 0.6 | 0         |
| 614 | Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. <i>Blood</i> , 2015, 126, 3054-3054.  | 0.6 | 0         |
| 615 | Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. <i>Blood</i> , 2015, 126, 4251-4251.   | 0.6 | 0         |
| 616 | Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. <i>Blood</i> , 2015, 126, 1074-1074.   | 0.6 | 0         |
| 617 | Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. <i>Blood</i> , 2015, 126, 4242-4242.  | 0.6 | 0         |
| 618 | Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens. <i>Blood</i> , 2016, 128, 4446-4446. | 0.6 | 0         |
| 619 | Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. <i>Blood</i> , 2016, 128, 4488-4488. | 0.6 | 0         |
| 620 | Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. <i>Blood</i> , 2016, 128, 2954-2954.   | 0.6 | 0         |
| 621 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.  | 0.6 | 0         |
| 622 | Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 3259-3259.   | 0.6 | 0         |
| 623 | Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 4490-4490.  | 0.6 | 0         |
| 624 | Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.   | 0.6 | 0         |
| 625 | Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Blood</i> , 2016, 128, 4492-4492.  | 0.6 | 0         |
| 626 | Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 8003-8003.  | 0.8 | 0         |
| 627 | Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.  | 0.6 | 0         |
| 628 | Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo. <i>Blood</i> , 2018, 132, 3214-3214.   | 0.6 | 0         |
| 629 | Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. <i>Blood</i> , 2018, 132, 3246-3246.  | 0.6 | 0         |
| 630 | OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S23-S24.   | 0.2 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 631 | P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S104.   | 0.2 | 0         |
| 632 | P-009: Assessing the predictive utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: a systematic literature review and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S43-S44.   | 0.2 | 0         |
| 633 | Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.  | 0.6 | 0         |
| 634 | Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine. <i>Blood</i> , 2021, 138, 3802-3802.   | 0.6 | 0         |
| 635 | Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients. <i>Blood</i> , 2021, 138, 1599-1599.   | 0.6 | 0         |
| 636 | Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. <i>Blood</i> , 2021, 138, 723-723.  | 0.6 | 0         |
| 637 | The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. <i>Blood</i> , 2021, 138, 2394-2394.   | 0.6 | 0         |
| 638 | Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. <i>Blood</i> , 2021, 138, 4771-4771.  | 0.6 | 0         |
| 639 | Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy. <i>Blood</i> , 2021, 138, 3799-3799.  | 0.6 | 0         |
| 640 | Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenström's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination. <i>Blood</i> , 2021, 138, 3791-3791.   | 0.6 | 0         |
| 641 | De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment. <i>HemaSphere</i> , 2021, 5, e665.   | 1.2 | 0         |
| 642 | Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study. <i>Blood</i> , 2021, 138, 1672-1672. | 0.6 | 0         |
| 643 | Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. <i>Blood</i> , 2021, 138, 3752-3752.   | 0.6 | 0         |
| 644 | IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.  | 0.6 | 0         |
| 645 | A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.   | 0.6 | 0         |
| 646 | Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020, 136, 19-20.  | 0.6 | 0         |
| 647 | Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.   | 0.6 | 0         |
| 648 | Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. <i>Blood</i> , 2020, 136, 33-34.  | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 649 | The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7. | 0.6 | 0         |
| 650 | Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. <i>Blood</i> , 2020, 136, 18-18.   | 0.6 | 0         |
| 651 | Author's reply: To PMID 23705905. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 300.   | 0.9 | 0         |
| 652 | Daratumumab for Immunoglobulin Light Chain Amyloidosis. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 79.                      | 0.1 | 0         |